A Phase II Evaluation Of Gleevec (NCI-Supplied Agent: STI571 [Imatinib Mesylate], IND 61135, NSC 716051) In The Treatment Of Recurrent Or Persistent Carcinosarcoma Of The Uterus.
Phase of Trial: Phase II
Latest Information Update: 06 Dec 2017
At a glance
- Drugs Imatinib (Primary)
- Indications Uterine cancer
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 17 Aug 2010 Actual end date (Jul 2010) added as reported by ClinicalTrials.gov.
- 17 Aug 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.